Spotlight on Oncology

Credits: 1.00 CME / CNE / CPE
Expert Perspectives on Improving Treatment of Patients with B-cell Non Hodgkin Lymphomas
Thomas Witzig, MD
Rush University Medical Center

Expert Perspectives on Improving Treatment of Patients with B-cell Non Hodgkin Lymphomas

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: November 9, 2018
Expires: November 8, 2019
60 minutes to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

Healthcare providers who are involved with the treatment of patients with B-cell lymphomas

Learning Objectives

After completing this program, participants should be able to:

  • Summarize current best-practice approaches for treatment of patients with different subtypes of indolent and aggressive B-cell non-Hodgkin lymphomas (NHLs)
  • Asses recent clinical advances and emerging treatment options for the management of B-cell NHLs, including next generation mAbs, BTK inhibitors, PI3K inhibitors, IMiDs, Bcl-2 inhibitors, and ongoing clinical trials
  • Evaluate patient, disease, and treatment-related considerations to optimize patient outcomes while providing the best standard of care for patients with B-cell NHLs

Activity Description

This activity provides healthcare providers with much needed professional education on treatment algorithms; recent clinical advances, emerging treatments, and clinical trials; as well as considerations to optimize patient outcomes while providing the best standard of care for patients with B-cell NHLs.

Faculty

Thomas E. Witzig, MD
Professor of Medicine Mayo Clinic College of Medicine
Co-PI, University of Iowa/Mayo Clinic Lymphoma SPORE
Deputy Director of Clinical Research, Mayo Clinic Cancer Center
Rochester, MN


Conflict of Interest Policy/Disclosure Statement

Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.

It is the policy of the Rush University Office of Interprofessional Continuing Education to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE. Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest (including but not limited to pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic) within the preceding 12 months.

The course directors, planners and faculty of this activity have the following relevant financial relationships to disclose.

Thomas E. Witzig, MD
Research Grant: Celgene, Novartis, Acerta - for research trial expenses, no personal money received
Consultant: Celgene (personally uncompensated)

Michaela Ryan, PhD
Nothing to disclose

Beth-Anne M. Christopher, MS, RN, CNL
Nothing to disclose

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing education unit(s) in Pharmacy. UAN: JA0000275-0000-18-130-H01-P.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 75% or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Inc., Celgene Corp., Novartis, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., AbbVie, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions About the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Oncology Presentations

0.50 CME / CNE
AXIS
Using “Rapid Progression” and Response Levels as Prognostic Markers in Selecting Optimal Second-Line Therapy for NSCLC

Using “Rapid Progression” and Response Levels as Prognostic Markers in Selecting Optimal Second-Line Therapy for NSCLC

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credits
0.5 Contact Hour(s)
Released: August 8, 2018
Expires: August 7, 2019
30 minutes to complete

Provided by

This educational activity is provided by

Target Audience

This activity is intended for medical oncologists, thoracic oncologists, pulmonologists, pathologists, oncology nurses, and other healthcare professionals involved in the treatment of NSCLC.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Analyze treatment options for patients with advanced NSCLC that does not have an actionable mutation target and has progressed on or after prior platinum-based therapy
  • Develop treatment plans for patients with advanced NSCLC without targetable activating mutations that has progressed on or after prior platinum-based therapy according to clinical practice guidelines
  • Select appropriate treatment for NSCLC without targetable activating mutations that has progressed rapidly on initial platinum-based therapy

Activity Description

Lung cancer continues to be the leading cause of cancer death in the United States, accounting for 27% of all cancer deaths in males and 25% in females. Non–small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancer cases. The prognosis of patients with NSCLC is poor; the 5-year overall survival (OS) rate is 5% for those with metastatic disease and 18% across all stages. Approximately 70% of patients with lung cancer have advanced or metastatic disease at initial diagnosis.

The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF mutations has led to an improvement in OS and progression-free survival by identifying subgroups of patients who benefit from targeted treatment. “Although recent advances have improved clinical outcomes for patients with tumors harboring targetable driver mutations, most NSCLC tumors lack these mutations, highlighting the need for novel therapeutic interventions… Patients with advanced NSCLC that is aggressive and rapidly progresses after first-line treatment have a poor prognosis and have been studied in several trials” (Reck et al, 2017).

This activity will review available treatment options, current guideline recommendations, and recent data about disease that has progressed rapidly on initial therapy to inform appropriate treatment selection.

Statement of Educational Need

The goal of this activity is to provide clinicians with the latest advances in the treatment of patients with advanced NSCLC without targetable activating mutations that has progressed on prior platinum-based therapy, including patients with disease that has progressed rapidly on initial therapy.

Faculty

Stephen V. Liu, MD
Associate Professor of Medicine
Lombardi Comprehensive Cancer Center
Georgetown University School of Medicine
Washington, DC


Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Stephen V. Liu, MD, reported a financial interest/relationship or affiliation in the form of Advisor/Consultant, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Co, Celgene Corp, Genentech/Roche, Ignyta, Lilly USA, Pfizer, Inc, Taiho Pharmaceutical Co, Ltd, Takeda Oncology; Contracted research, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Corvus Pharmaceuticals, Esanex Inc, Genentech, Inc, Ignyta, Lycera, MedImmune, Merck & Co, Inc, OncoMed Pharmaceuticals, Pfizer, Inc, Threshold Pharmaceuticals.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn Haas, PhD, RN, CNS, ANP-BC; and Stephanie Sutphin, PharmD,hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Designation of Credit

Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 100% and the post-activity evaluation, your certificate will be made available immediately.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 MOC / CME / CNE
The France Foundation
PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Understanding and Applying PARP Inhibitor Data to Selection and Monitoring

PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Understanding and Applying PARP Inhibitor Data to Selection and Monitoring

Start

Activity Details

Free CME/MOC/CNE
0.25 AMA PRA Category 1 Credits™/
MOC Points
0.25 Contact Hour(s)
Released: December 20, 2018
Expires: December 19, 2019
15 minutes to complete

Jointly Provided by

Target Audience

This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).

Learning Objectives

  • Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
  • Interpret the results of genomic testing accurately, including working effectively with genetic counselors
  • Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
  • Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families

Activity Description

This case-based webinar includes implications of genetic testing for treatment decisions, and reviews the safety and efficacy of FDA-approved PARP inhibitors for patients with metastatic or advanced breast cancer with germline BRCA mutations.

Statement of Educational Need

MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.

Faculty

Joy Larsen Haidle, MS, CGC
Ruth M. O’Regan, MD
Associate Director, Clinical Research
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

The following faculty report that they have relevant financial relationships to disclose:
  • Ruth O’Regan, MD, has done contract research for Eisai, Novartis and Pfizer, Inc. Dr. O’Regan has served as an advisor for Genentech, Immunogenics, Lilly, MacroGenics, Novartis, Pfizer, Inc. and Puma.


Jennie Petruney, ANP
Nurse Practitioner
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

The following faculty report that they have no relevant financial relationships to disclose:
  • Jennie Petruney, ANP

MOC Reviewers

Theodore Bruno, MD
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut

The following faculty report that they have relevant financial relationships to disclose:
  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.


Patrick Thomas Grogan, MD, PhD
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin

The following faculty report that they have no relevant financial relationships to disclose:
  • Patrick Thomas Grogan, MD, PhD

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of TFF, ACCC and ONS. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

The Oncology Nursing Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Participants in PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Understanding and Applying PARP Inhibitor Data to Selection and Monitoring can earn a maximum of 0.25 contact hours of CNE upon the successful completion of this continuing education activity. No partial credit will be given. Participants must view sessions in their entirety and submit a completed evaluation within the specified time frame to receive CNE credit. NOTE: It is not required to complete all three parts of the series to claim your CNE certificate for one of the parts.

ANCC

ILNA Information 
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. CNE sessions have been classified into the following ILNA categories for all certification renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON)  

  • Coordination of Care – 0.25 points
  • Diagnosis and Staging – 0.25 points
  • Treatment – 0.25 points

Method of Participation / How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 MOC / CME / CNE
The France Foundation
PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Future Vision

PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Future Vision

Start

Activity Details

Free CME/MOC/CNE
0.50 AMA PRA Category 1 Credits™/
MOC Points
0.50 Contact Hour(s)
Released: December 20, 2018
Expires: December 19, 2019
30 minutes to complete

Jointly Provided by

Target Audience

This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).

Learning Objectives

  • Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
  • Interpret the results of genomic testing accurately, including working effectively with genetic counselors
  • Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
  • Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families

Activity Description

This webinar provides an overview of PARP inhibitor therapy for patients with breast cancer, including use as single-agent therapy, and ongoing studies evaluating PARP inhibitors in combination with chemotherapy and immunotherapy for this patient population.

Statement of Educational Need

MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.

Faculty

Joy Larsen Haidle, MS, CGC
Ruth M. O’Regan, MD
Associate Director, Clinical Research
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

The following faculty report that they have relevant financial relationships to disclose:
  • Ruth O’Regan, MD, has done contract research for Eisai, Novartis and Pfizer, Inc. Dr. O’Regan has served as an advisor for Genentech, Immunogenics, Lilly, MacroGenics, Novartis, Pfizer, Inc. and Puma.


Carol K. Tweed, MD
Medical Oncologist
Anne Arundel Medical Center
Annapolis, Maryland

The following faculty report that they have relevant financial relationships to disclose:
  • Carol K. Tweed, MD, has served on an advisory board for AstraZeneca. She has served on a Non-CE speakers bureau for Genomic Health.

MOC Reviewers

Theodore Bruno, MD
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut

The following faculty report that they have relevant financial relationships to disclose:
  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.


Patrick Thomas Grogan, MD, PhD
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin

The following faculty report that they have no relevant financial relationships to disclose:
  • Patrick Thomas Grogan, MD, PhD

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of TFF, ACCC and ONS. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

The Oncology Nursing Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Participants in PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Future Vision can earn a maximum of 0.50 contact hours of CNE upon the successful completion of this continuing education activity. No partial credit will be given. Participants must view sessions in their entirety and submit a completed evaluation within the specified time frame to receive CNE credit. NOTE: It is not required to complete all three parts of the series to claim your CNE certificate for one of the parts.

ANCC

ILNA Information 
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. CNE sessions have been classified into the following ILNA categories for all certification renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON)  

  • Diagnosis and Staging – 0.50 points
  • Treatment – 0.50 points

Method of Participation / How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 MOC / CME / CNE
The France Foundation
PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Appropriate Genetic Testing and Implications for Targeted Therapy Use

PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Appropriate Genetic Testing and Implications for Targeted Therapy Use

Start

Activity Details

Free CME/MOC/CNE
0.75 AMA PRA Category 1 Credits™/
MOC Points
0.75 Contact Hour(s)
Released: December 20, 2018
Expires: December 19, 2019
45 minutes to complete

Jointly Provided by

Target Audience

This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).

Learning Objectives

  • Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
  • Interpret the results of genomic testing accurately, including working effectively with genetic counselors
  • Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
  • Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families

Activity Description

This case-based webinar reviews criteria for BRCA1/2 testing, the importance of obtaining family history for patients with cancer, interpretation of genetic testing results for patients with metastatic breast cancer and their families, and ways to access genetic services.

Statement of Educational Need

MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.

Faculty

Joy Larsen Haidle, MS, CGC
Joy Larsen Haidle, MS, CGC
Genetic Counselor
North Memorial Health Cancer Center
Robbinsdale, Minnesota

The following faculty report that they have no relevant financial relationships to disclose:
  • Joy Larsen Haidle, MS, CGC


Carol K. Tweed, MD
Medical Oncologist
Anne Arundel Medical Center
Annapolis, Maryland

The following faculty report that they have relevant financial relationships to disclose:
  • Carol K. Tweed, MD, has served on an advisory board for AstraZeneca. She has served on a Non-CE speakers bureau for Genomic Health.

MOC Reviewers

Theodore Bruno, MD
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut

The following faculty report that they have relevant financial relationships to disclose:
  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.


Patrick Thomas Grogan, MD, PhD
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin

The following faculty report that they have no relevant financial relationships to disclose:
  • Patrick Thomas Grogan, MD, PhD

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of TFF, ACCC and ONS. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

The Oncology Nursing Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Participants in PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Appropriate Genetic Testing and Implications for Targeted Therapy Use can earn a maximum of 0.75 contact hours of CNE upon the successful completion of this continuing education activity. No partial credit will be given. Participants must view sessions in their entirety and submit a completed evaluation within the specified time frame to receive CNE credit. NOTE: It is not required to complete all three parts of the series to claim your CNE certificate for one of the parts.

ANCC

ILNA Information 
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. CNE sessions have been classified into the following ILNA categories for all certification renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON).

  • Diagnosis and Staging – 0.75 points 
  • Treatment – 0.75 points

Method of Participation / How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME / CNE / CPE
Rush University Medical Center
Expert Perspectives on Improving Treatment of Patients with B-cell Non Hodgkin Lymphomas

Expert Perspectives on Improving Treatment of Patients with B-cell Non Hodgkin Lymphomas

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: November 9, 2018
Expires: November 8, 2019
60 minutes to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

Healthcare providers who are involved with the treatment of patients with B-cell lymphomas

Learning Objectives

After completing this program, participants should be able to:

  • Summarize current best-practice approaches for treatment of patients with different subtypes of indolent and aggressive B-cell non-Hodgkin lymphomas (NHLs)
  • Asses recent clinical advances and emerging treatment options for the management of B-cell NHLs, including next generation mAbs, BTK inhibitors, PI3K inhibitors, IMiDs, Bcl-2 inhibitors, and ongoing clinical trials
  • Evaluate patient, disease, and treatment-related considerations to optimize patient outcomes while providing the best standard of care for patients with B-cell NHLs

Activity Description

This activity provides healthcare providers with much needed professional education on treatment algorithms; recent clinical advances, emerging treatments, and clinical trials; as well as considerations to optimize patient outcomes while providing the best standard of care for patients with B-cell NHLs.

Faculty

Thomas E. Witzig, MD
Professor of Medicine Mayo Clinic College of Medicine
Co-PI, University of Iowa/Mayo Clinic Lymphoma SPORE
Deputy Director of Clinical Research, Mayo Clinic Cancer Center
Rochester, MN


Conflict of Interest Policy/Disclosure Statement

Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.

It is the policy of the Rush University Office of Interprofessional Continuing Education to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE. Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest (including but not limited to pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic) within the preceding 12 months.

The course directors, planners and faculty of this activity have the following relevant financial relationships to disclose.

Thomas E. Witzig, MD
Research Grant: Celgene, Novartis, Acerta - for research trial expenses, no personal money received
Consultant: Celgene (personally uncompensated)

Michaela Ryan, PhD
Nothing to disclose

Beth-Anne M. Christopher, MS, RN, CNL
Nothing to disclose

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing education unit(s) in Pharmacy. UAN: JA0000275-0000-18-130-H01-P.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 75% or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Inc., Celgene Corp., Novartis, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., AbbVie, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions About the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME
University of Nebraska Medical Center
The Next Steps in CAR T-Cell Therapy for the Treatment of Patients With Lymphoma

The Next Steps in CAR T-Cell Therapy for the Treatment of Patients With Lymphoma

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credits
Released: August 31, 2018
Expires: August 31, 2019
20 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Provider

This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Target Audience

The target audience for this activity is for community and academic medical oncologists, hematologists, advanced practitioners, and other clinicians who treat patients with lymphoma.

Learning Objectives

After completing this activity, participants should be better able to:

  • Review clinical trial data that led to approval of CAR T-cell–based therapies for the treatment of patients with lymphoma
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with lymphoma, including various combination strategies being examined
  • Develop strategies to mitigate adverse events often encountered with the use of CAR T-cell therapy, including cytokine release syndrome and neurotoxicity

Activity Description

Expert Insights is an interview involving 2 world renowned experts actively engaged in treatment of patients with lymphoma. This discussion features expert summary and interpretation of data presented during the 2018 Pan Pacific Lymphoma Conference in Hawaii, as well as provide guidance on the optimal use of current and emerging therapies.

Statement of Educational Need

CD19-targeted CAR T cells have emerged as a highly effective therapy in patients with NHL. However, multiple CAR T-cell technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with aggressive NHL need expert guidance to evaluate clinical data on CAR T-cell therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.

Faculty

Julie M. Vose, MD, MBA - Moderator
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Grants/Research Support: Acerta Pharma, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Kite Pharma, Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Novartis, Seattle Genetics, Inc.

Consultant Fees, Honorarium: AbbVie Inc., Epizyme, Inc., Karyopharm Therapeutics, Legend Pharmaceuticals, Novartis, Roche, Sandoz, Vaniam Group LLC


Sattva S. Neelapu, MD
Professor
Deputy Department Chair ad interim
Director of Laboratory and Translational Research
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Grants/Research Support, Advisor: Acerta Pharma, Bristol-Myers Squibb Company, Cellectis, Gilead, Karus, Kite, A Gilead Company, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Poseida

Consultant, Advisor: Celgene Corporation, Kite, A Gilead Company, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Novartis, Unum Therapeutics


Conflict of Interest Policy/Disclosure Statement

As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.

The following indicates the disclosure declaration information and the nature of those commercial relationships.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

Educational grant support provided by Celgene Corporation and Kite, A Gilead Company.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

University of Nebraska Medical Center, Center for Continuing Education
Brenda Ram, CMP, CHCP
bram@unmc.edu
402-559-9250

Bio Ascend
meetings@bioascend.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CNE / CPE
AXIS
Nursing and Pharmacy Provisions of Care for HR+/HER2− Advanced or Metastatic Breast Cancer: Spotlight on CDK 4/6 Inhibitors

Nursing and Pharmacy Provisions of Care for HR+/HER2− Advanced or Metastatic Breast Cancer: Spotlight on CDK 4/6 Inhibitors

Start

Activity Details

Free CPE/CNE
1.0 Contact Hour
Released: August 27, 2018
Expires: August 26, 2019
1 hour to complete

Provided by

This educational activity is provided by

Target Audience

This activity is intended for oncology nurses, advanced practitioners, pharmacists, pharmacy technicians, and other allied healthcare professionals involved in the team-based management of breast cancer.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Discuss the risks, benefits, and differentiation points among CDK 4/6 inhibitors for the treatment of HR-positive/HER2-negative advanced breast cancer with the healthcare team and patients.
  • Evaluate proper dosing and administration of oral CDK 4/6 inhibitors used in the treatment of HR-positive/HER2-negative advanced breast cancer.
  • Enhance patient education through shared decision-making strategies regarding therapy selection and the importance of oral therapy compliance to maximize therapeutic outcomes.
  • Educate patients on potential adverse events associated with CDK 4/6 inhibitors.
  • Develop strategies to anticipate, monitor and manage adverse events with oral CDK 4/6 inhibitors for the treatment of HR-positive/HER2-negative advanced breast cancer to maximize the benefits of these therapies.

Activity Description

The American Cancer Society estimated that in 2017 there were 255,180 new cases of breast cancer and 41,070 deaths due to breast cancer in the United States. Nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and, therefore, are not candidates for HER2-targeting therapies.

Significant advances include the development of agents that target critical pathways involved in resistance to endocrine therapy, such as cyclin-dependent kinase (CDK) 4/6 inhibitors. Differentiating among the agents that comprise this novel class will be essential practice skills that oncology advanced practitioners such as nurses and pharmacists will need to become more familiar with to advance patient care and support.

New oral agents are revolutionizing breast cancer care, and data show that patient adherence to the full duration of therapy is critical to realize the positive effects of these agents on tumor control and patient survival. Nurses and pharmacists can play a critical role in improving patient adherence to oral therapy, from treatment decision support and monitoring to management and patient counseling.

This activity will review these oral therapies, including risk and benefits, barriers to adherence, side effect monitoring and management and patient counseling on aspects such as dosing and safe handling of oral therapies. This will be coupled with education about shared decision-making strategies to achieve increased patient satisfaction, better adherence to treatment plans, greater treatment engagement, and better quality decision making.

Statement of Educational Need

The goal of this activity is to provide education about oral CDK 4 and 6 inhibitors for the treatment of HR+/HER2− advanced or metastatic breast cancer so nurses, pharmacists, and other healthcare professionals are able to educate, counsel, and support patients regarding benefits, dosing, adherence, and side effects of therapies to make informed decisions with the goal of improving patient outcomes.

Faculty

Pharmacy Co-Chairperson
Michael L. Brandt, PharmD, FASHP
Oncology Infusion Pharmacist
Cancer and Blood Specialties Center
Rockwood Clinic, MultiCare Health System
Spokane, Washington


Nurse Co-Chairperson
Jacquelyn H. Lauria, MS, RN, APN-C, AOCNP®
Advanced Practice Nurse
Rutgers Cancer Institute of New Jersey
Stacy Goldstein Breast Center
New Brunswick, New Jersey

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter

Reported Financial Relationship

Michael L. Brandt, PharmD, FASHP

Michael L. Brandt, PharmD, FASHP, has no real or apparent conflicts of interest to report

Jacquelyn H. Lauria, MS, RN, APN-C, AOCNP®

Jacquelyn H. Lauria, MS, RN, APN-C, AOCNP®, reported a financial interest/relationship or affiliation in the form of Serve(d) as a speaker or a member of a speakers bureau for: PUMA Biotechnology


The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Stephanie Sutphin, PharmD; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Credit Designation for Pharmacists/Pharmacy Technicians
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education credit (JA4008106-0000-18-039-H01-P and JA4008106-0000-18-039-H01-T).

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. Pharmacists – your record will be loaded to CPE Monitor.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
University of Nebraska Medical Center
The Time is Now: Focusing on New and Emerging Therapies for Improving Patient Outcomes in AML

The Time is Now: Focusing on New and Emerging Therapies for Improving Patient Outcomes in AML

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit
Released: August 20, 2018
Expires: August 20, 2019
45 minutes to complete

Accredited By

University of Nebraska Medical Center, Center for Continuing Education

Provided By


This activity is co-provided by University of Nebraska Medical Center, Center for Continuing Education and Integrity Continuing Education, Inc.

Target Audience

This program is intended for hematologists, medical oncologists, health system pharmacists, oncology nurses, nurse practitioners, physician assistants, and other healthcare providers involved in the care of patients with AML.

Learning Objectives

Upon completion of this educational activity, participants should be better able to:

  • Describe the pathophysiology of AML and identify potential therapeutic targets
  • Summarize current clinical trial evidence regarding the efficacy and safety of new and emerging therapies for AML
  • Outline an approach to AML treatment selection that is tailored based upon individual patient characteristics

Activity Description

Despite recent advances in understanding of the pathophysiology of AML and a corresponding expansion of targeted treatment modalities, the care of individuals with the disease remains a significant challenge in current clinical practice. The following program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote accurate disease classification and risk assessment, and personalized treatment for patients with AML, including older individuals and those with relapsing or refractory disease.

Faculty

Jorge E. Cortes, MD
Jorge E. Cortes, MD
Jane and John Justin Distinguished Chair in Leukemia Research
Section Chief of AML & CML
Deputy Chairman
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas


Richard M. Stone, MD
Richard M. Stone, MD
Professor of Medicine
Harvard Medical School
Chief of Staff
Director, Adult Acute Leukemia Program
Dana-Farber Cancer Institute
Boston, Massachusetts


Conflict of Interest Policy/Disclosure Statement

The University of Nebraska Medical Center, Center for Continuing Education and Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by The University of Nebraska Medical Center, Center for Continuing Education and Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Jorge E. Cortes, MD, has no real or apparent conflicts of interest to report.

Richard M. Stone, MD
Consultant: Abbvie, Agios, Amgen, Argenix, Arog, Astellas, Celator, Celgene, Cornerstone, Fujifilm, Janssen, Jazz, Juno, Karyopharm, Merck, Novartis, Ono, Orsenix, Otsuka, Pfizer
Research: Agios, Arog, Novartis
Board Member: Actinium
Steering Committee: Celgene

Patima Tanapat, PhD, has no real or apparent conflicts of interest to report.

Accreditation Statement for Physicians

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of August 20, 2018 through August 20, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The University of Nebraska Medical Center, Center for Continuing Education, Integrity Continuing Education, Inc. and Pfizer do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about this activity, please contact the University of Nebraska Medical Center, Center for Continuing Education at (402) 559-4152 or via email at conted@unmc.edu.

1.00 CME / CNE
AcademicCME
The Increasing Role of Biosimilars in Oncology

The Increasing Role of Biosimilars in Oncology

Start

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: June 15, 2018
Expires: September 17, 2019
1 hour to complete

Accredited By

Target Audience

Oncologists, primary care physicians, internists and advanced practice providers, including NPs and PAs, responsible for the diagnosis, treatment or management of patients with various cancers

Learning Objectives

  • Understand the fundamentals of biosimilars in oncology, including bioequivalence, totality of evidence, and interchangeability.
  • Evaluate the current clinical trial data of biosimilars for the treatment of various oncologic therapeutic areas.
  • Utilize the health care team and shared decision making to achieve improved outcomes in patients with various cancers.

Activity Description

This continuing education activity will focus on recent clinical trial data as well as therapeutic advances in the increasing role of biosimilars in oncology. The three expert faculty will review the fundamentals of biosimilars in oncology, including bioequivalence, totality of evidence, and interchangeability. A review of current clinical trial data of biosimilars for the treatment of various oncologic therapeutic areas will be presented. The faculty will discuss how to utilize the health care team and shared decision making to achieve improved outcomes in patients with various cancers. Upon completion of this activity, learners will gain knowledge on how to implement biosimilars in their treatment strategies for oncology patients.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding use of biosimilars and their role in modern day medicine.

Agenda

  1. A Scientific Overview of Biosimilars in Oncology
  2. A Clinical Analysis of Emerging Biosimilars in Oncology
  3. The Importance of Utilizing the Health Care Team and Shared Decision Making to Achieve Improved Outcomes

Faculty

Sanjiv S. Agarwala, MD
Chief of Medical Oncology and Hematology
St Luke's University Hospital and Health Network
Professor of Medicine
Temple University School of Medicine
Philadelphia, Pennsylvania


Amy Goodrich, RN, BSN, MSN, CRNP-AC
Research Associate
The Johns Hopkins School of Medicine
Nurse Practitioner
The Sidney Kimmel Cancer Center at Johns Hopkins
Baltimore, Maryland


Wasif M. Saif, MD, MBBS
Professor of Medicine
Director, GI Oncology Program
Program Leader, Experimental Therapeutics
Tufts Medical Center
Boston, Massachusetts


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

Sanjiv S. Agarwala, MD
Nothing to disclose.

Amy Goodrich, RN, BSN, MSN, CRNP-AC
Consultant/Advisor: Gilead
Speaker's Bureau: Gilead

Wasif M. Saif, MD, MBBS
Grant/Research Support: TAIHO ONCOLOGY, INC.
Speaker's Bureau: TAIHO ONCOLOGY, INC.

Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring; Chelsey Benedek; and Kim Cheramie, MSN, RN-BC, hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or Review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  • All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

Statement of Commercial Support

This activity has been supported by educational grants from Amgen Inc. and Boehringer Ingelheim.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Amgen Inc. and Boehringer Ingelheim do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.